Galapagos, OneWorld Health to collaborate on drugs to treat diarrheal diseases

By E. Janene Geiss

Philadelphia, Sept. 6 - Galapagos NV said Wednesday that its service division, BioFocus DPI, has entered into a drug discovery collaboration with the Institute for OneWorld Health, a non-profit pharmaceutical company based in San Francisco.

OneWorld Health is working on a number of drug development initiatives for neglected diseases, with support from the Bill & Melinda Gates Foundation and other donors, the Mechelen, Belgium, biotechnology company said in a news release.

The collaboration focuses on the development of new drugs to combat diarrheal diseases, a fundamental threat to the health of children in the developing world.

Under the agreement, BioFocus will apply its medicinal chemistry expertise to identify new drug candidates for OneWorld Health's diarrheal disease program.

Total contract value for Galapagos exceeds €3 million over two and a half years, officials said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.